• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Germany·Healthcare·AJ91.DE
Share

DocCheck AG Stocks

€ 12.5Last Updated 12.06.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

€ 74.36M

€ 12.5
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Cologne, Germany, DocCheck AG specializes in delivering a comprehensive suite of services to Europe's healthcare industry. These offerings encompass strategic marketing, customer relationship management (CRM), and e-commerce solutions. A key component of their operation is the DocCheck portal, an online hub designed for information exchange and providing various digital and e-commerce functionalities to market participants. Beyond these, DocCheck AG devises and executes communication strategies across both traditional and nascent media channels, catering to both the healthcare and business-to-business (B2B) sectors. Additionally, the company actively fosters innovation by providing seed funding to promising healthcare startups.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, reasonably priced on P

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 16:01

Highlights in small-caps: record IPO in biotech, Wizz Air success, SpaceX effect

13.06.2026 13:01

An investment idea for all times, IPO of the year and how to keep emotions in check in the stock market

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026